CMAB008 Leiting produced by Taizhou Mabtech Pharmaceutical. [Photo/WeChat account: weigg6666]
The Reminton Infliximab 100mg Powder for Concentrate for Solution for Infusion, or CMAB008 Leiting, developed by Taizhou Mabtech Pharmaceutical, located in China Medical City, Taizhou, Jiangsu province, was recently approved for market by the Malaysian National Pharmaceutical Regulatory Agency.
This marked substantial progress in the commercialization process of this product in the Southeast Asian market. The product was approved for market by the National Medical Products Administration in July 2021.
This drug is suitable for treating various diseases such as rheumatoid arthritis, Crohn's disease in adults and children over 6 years old, fistulous Crohn's disease, ankylosing spondylitis, psoriasis, and ulcerative colitis in adults.
Founded in 2015, Mabtech is a wholly-owned subsidiary of HK based Mabpharm.
Mabtech's progress injects strong momentum into China Medical City to strive for the goal of China's first and world's famous pharmaceutical hub.
Taizhou Mabtech Pharmaceutical. [Photo/WeChat account: weigg6666]